Stock 688289 SANSURE BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sansure Biotech Inc.

Equities

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
19.07 CNY +1.44% Intraday chart for Sansure Biotech Inc. +3.70% -2.46%
02-29 Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84% MT
02-28 Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 45,580 23,600 12,747 11,187 10,912 -
Enterprise Value (EV) 1 45,580 23,600 12,747 11,187 10,912 10,912
P/E ratio 17.4 x 10.5 x 6.63 x 31.5 x 45.4 x 29.3 x
Yield - - - - - -
Capitalization / Revenue 9,561,298 x 5,227,554 x - 11,114,796 x - -
EV / Revenue 9,561,298 x 5,227,554 x - 11,114,796 x - -
EV / EBITDA 14,633,822 x 8,830,047 x - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 9.62 x 3.71 x - - - -
Nbr of stocks (in thousands) 592,000 592,000 580,726 572,209 572,209 -
Reference price 2 76.99 39.86 21.95 19.55 19.07 19.07
Announcement Date 25/02/21 24/02/22 18/04/23 28/02/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 365.4 4,767 4,515 - 1,006 - -
EBITDA - 3,115 2,673 - - - -
EBIT - 3,085 2,622 - - - -
Operating Margin - 64.72% 58.07% - - - -
Earnings before Tax (EBT) - 3,069 2,616 - - - -
Net income - 2,616 2,243 1,937 360.2 - -
Net margin - 54.87% 49.68% - 35.79% - -
EPS 1 0.0743 4.419 3.791 3.310 0.6200 0.4200 0.6500
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 09/08/20 25/02/21 24/02/22 18/04/23 28/02/24 - -
1CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 208
Net margin -
EPS 2 0.3500
Dividend per Share -
Announcement Date 30/10/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 127 165 4,137 4,668 5,636 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 67.3 -94.1 1,780 899 1,293 -
ROE (net income / shareholders' equity) 1.74% 8.28% 98.7% 40.3% 27.9% 4.82%
ROA (Net income/ Total Assets) 0.44% 3.59% 62.9% 25.2% 16.9% -
Assets 1 1,540 1,100 4,158 8,912 11,486 -
Book Value Per Share - 1.050 8.020 10.80 13.00 -
Cash Flow per Share - 0.1900 4.380 4.450 5.550 -
Capex 1 32.9 34.1 109 373 559 -
Capex / Sales 10.84% 9.34% 2.28% 8.26% 8.66% -
Announcement Date 09/08/20 09/08/20 29/03/21 18/04/22 18/04/23 28/02/24
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
SANSURE BIOTECH INC. Stock Sansure Biotech Inc.
-2.46% 1.51B
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688289 Stock
  4. Financials Sansure Biotech Inc.